Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Non-Current Liabilities (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 2.41% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Dec 2025, down 2.41%, and an annual FY2025 reading of $2.3 million, down 2.41% over the prior year.
  • Other Non-Current Liabilities was $2.3 million for Q4 2025 at Cytek Biosciences, down from $2.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.5 million in Q3 2025 and bottomed at $737000.0 in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $1.8 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 94.98% in 2022, then dropped 12.13% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $1.2 million in 2021, then skyrocketed by 31.81% to $1.6 million in 2022, then soared by 53.18% to $2.4 million in 2023, then decreased by 2.76% to $2.4 million in 2024, then fell by 2.41% to $2.3 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CTKB at $2.3 million in Q4 2025, $2.5 million in Q3 2025, and $2.5 million in Q2 2025.